Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026

Reuters01-05

Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026

Protalix BioTherapeutics Inc. announced that it enters 2026 with a profitable commercial business through its partners and a focused pipeline targeting high unmet medical needs. The company expects future sales to continue being anchored by Elfabrio, marketed by partner Chiesi in the United States and key international markets. Protalix projects that Elfabrio is positioned to capture 15% to 20% of the global Fabry market, which is estimated to reach approximately $3.4 billion by 2030. The company remains committed to advancing its pipeline, including potential therapies for uncontrolled gout and rare renal diseases, while expanding its commercial footprint and pursuing strategic partnerships to accelerate growth and scale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN55872) on January 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2601885135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601885135","market":"fut","top_or_hot":-1,"title":"Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PLX\">Protalix BioTherapeutics Inc</a>. announced that it enters 2026 with a profitable commercial business through its partners and a focused pipeline targeting high unmet medical needs. The company expects future sales to continue being anchored by Elfabrio, marketed by partner Chiesi in the United States and key international markets. Protalix projects that Elfabrio is positioned to capture 15% to 20% of the global Fabry market, which is estimated to reach approximately $3.4 billion by 2030. The company remains committed to advancing its pipeline, including potential therapies for uncontrolled gout and rare renal diseases, while expanding its commercial footprint and pursuing strategic partnerships to accelerate growth and scale.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN55872) on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PLX\">Protalix BioTherapeutics Inc</a>. announced that it enters 2026 with a profitable commercial business through its partners and a focused pipeline targeting high unmet medical needs. The company expects future sales to continue being anchored by Elfabrio, marketed by partner Chiesi in the United States and key international markets. Protalix projects that Elfabrio is positioned to capture 15% to 20% of the global Fabry market, which is estimated to reach approximately $3.4 billion by 2030. The company remains committed to advancing its pipeline, including potential therapies for uncontrolled gout and rare renal diseases, while expanding its commercial footprint and pursuing strategic partnerships to accelerate growth and scale.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN55872) on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLX","symbol_name":"Protalix BioTherapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL6NBN02:1","article_id":"2601885135","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601885135","pubTimestamp":1767613816,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Protalix BioTherapeutics Inc. announced that it enters 2026 with a profitable commercial business through its partners and a focused pipeline targeting high unmet medical needs. The company expects future sales to continue being anchored by Elfabrio, marketed by partner Chiesi in the United States and key international markets. Protalix projects that Elfabrio is positioned to capture 15% to 20% of the global Fabry market, which is estimated to reach approximately $3.4 billion by 2030. The company remains committed to advancing its pipeline, including potential therapies for uncontrolled gout and rare renal diseases, while expanding its commercial footprint and pursuing strategic partnerships to accelerate growth and scale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLX":"Protalix BioTherapeutics Inc","BK4139":"生物科技"},"translate_title":"Protalix BioTherapeutics预计2026年Elfabrio销售将推动盈利增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLX":0.9},"content_text":"Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026\n    \n\nProtalix BioTherapeutics Inc. announced that it enters 2026 with a profitable commercial business through its partners and a focused pipeline targeting high unmet medical needs. The company expects future sales to continue being anchored by Elfabrio, marketed by partner Chiesi in the United States and key international markets. Protalix projects that Elfabrio is positioned to capture 15% to 20% of the global Fabry market, which is estimated to reach approximately $3.4 billion by 2030. The company remains committed to advancing its pipeline, including potential therapies for uncontrolled gout and rare renal diseases, while expanding its commercial footprint and pursuing strategic partnerships to accelerate growth and scale.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN55872) on January 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}